论文部分内容阅读
谱系特异性生长因子能动员外周血祖细胞(PBPC)、促进大剂量化疗后的造血恢复。重组人血小板生成素(rhTPO)可进一步增加祖细胞的含量、重建PBPC产物的潜能。作者通过对29例经大剂量化疗后再回输PBPC的乳癌患者进行观察,评价了rhTPO作为PBPC的动员剂与粒细胞集落刺激因子(G-CSF)联合应用的安全性能和活性效果。开始时,按逐步加大剂量的方法静脉注射给予患者单一剂量的rhTPO 0.6,1.2或2.4μg/kg体重/天。随后,给予rhPTO0.6或0.3μg/kg体重/-3,-1和1天,或者给予0.6μg/kg体重/-1和1天。从第3天开始在整个
Lineage-specific growth factors can mobilize peripheral blood progenitor cells (PBPCs) and promote hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) can further increase the content of progenitor cells and the potential of reconstructing PBPC products. The authors evaluated the safety and activity of rhTPO as a combination of mobilization of PBPC and granulocyte colony-stimulating factor (G-CSF) in 29 breast cancer patients who received high-dose chemotherapy and then returned to PBPC. At the beginning, a single dose of rhTPO 0.6, 1.2, or 2.4 μg/kg body weight/day was intravenously administered as a stepwise escalation. Subsequently, rhPTO was administered at 0.6 or 0.3 μg/kg body weight/-3,-1 and 1 day, or 0.6 μg/kg body weight/-1 and 1 day. From the 3rd day on the whole